Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bluefish pharmaceuticals ab - bicalutamide - oral tablet - 150mg

Ireland - English - HPRA (Health Products Regulatory Authority)

fair-med healthcare gmbh - bicalutamide - film-coated tablet - 150 milligram(s) - anti-androgens; bicalutamide

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. bicalutamide has no indication for women, and should not be used in this population. bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it c

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets, usp 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets, usp 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in females. there are no human data on t

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - bicalutamide - oral tablet - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - bicalutamide - oral tablet - 50mg